Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945904 | 0.79 | TYR (0.47) | ALDH1A1TSHRSMN1; SMN2HPGDAOX1 | |
| SCHEMBL1320276 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TSHRSMN1; SMN2HPGDAOX1 | |
| SCHEMBL23224343 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TSHRSMN1; SMN2TDP1CYP2A6 | |
| SCHEMBL8807188 | 0.75 | IDO1 (0.43) | ALDH1A1SMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL29820181 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TSHRSMN1; SMN2HPGDMEN1 | |
| SCHEMBL24666312 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TSHRSMN1; SMN2HPGDMEN1 | |
| SCHEMBL31039444 | 0.72 | ALDH1A1 (0.36) | ALDH1A1TSHRTRIM24TDP1TRIM33 | |
| SCHEMBL23257196 | 0.72 | ALDH1A1 (0.36) | ALDH1A1TSHRTRIM24TDP1TRIM33 | |
| SCHEMBL5496500 | 0.72 | APLNR (0.54) | ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL7531959 | 0.72 | ALDH1A1 (0.68) | ALDH1A1TSHRHPGDAOX1TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | ALDH1A1 786/4885TSHR 1732/4885SMN1; SMN2 1512/4885 |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | ALDH1A1 997/4885TSHR 1141/4885SMN1; SMN2 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.